LYELLyell Immunopharma, Inc.vs its industry peers
A metric-by-metric comparison of Lyell Immunopharma, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LYELThis | $260M#8 | — | 1.1x#3 | 7229.0x#12 | -41.0%#11 | 20.0%#5 | -748344.4%#13 | -117.4%#10 | — | — | -14.3%#11 | — |
| VNDA | $305M#1 | — | 1.4x#5 | 1.4x#3 | 8.7%#7 | -1066.7%#16 | -70.0%#4 | -100.1%#9 | — | — | 14.9%#8 | — |
| UPB | $290M#2 | — | 1.1x#2 | 101.7x#10 | 20.4%#6 | -128.4%#13 | -5618.8%#11 | -52.9%#6 | — | — | -66.9%#15 | — |
| FULC | $288M#3 | — | 0.9x#1 | — | -100.0%#14 | -670.0%#15 | — | -24.1%#4 | — | — | -48.4%#14 | — |
| PYXS | $281M#4 | — | 24.5x#10 | 20.3x#8 | -14.2%#10 | -3.0%#7 | -609.2%#8 | -696.0%#12 | — | — | 52.3%#6 | — |
| CUE | $268M#6 | — | 116.1x#12 | 9.8x#6 | 195.7%#2 | 34.6%#3 | -96.7%#5 | -1151.6%#13 | — | — | 67.1%#2 | — |
| TRDA | $269M#5 | — | 1.2x#4 | 10.6x#7 | -87.9%#12 | -319.0%#14 | -621.1%#9 | -61.6%#7 | — | — | 35.6%#7 | — |
| GLSI | $263M#7 | — | 84.3x#11 | — | — | -11.2%#8 | — | -621.1%#11 | — | — | 58.3%#4 | — |
| CAMP | $254M#10 | — | — | 72.7x#9 | 436.5%#1 | -55.2%#11 | -1502.4%#10 | — | — | — | 56.1%#5 | — |
| BCYC | — | — | — | — | 105.8%#3 | -29.5%#10 | -340.4%#7 | -42.9%#5 | -794.1%#2 | — | -46.8%#13 | — |
| MGNX | $260M#9 | — | 6.1x#8 | 1.7x#4 | -0.3%#9 | -11.4%#9 | -48.7%#3 | -0.2%#2 | — | — | 164.6%#1 | — |
| FHTX | $248M#11 | — | — | 8.0x#5 | 36.8%#5 | 14.2%#6 | -279.5%#6 | — | — | — | -14.2%#10 | — |
| RNAC | $241M#13 | — | — | 603.6x#11 | -99.0%#13 | -68.3%#12 | -35851.3%#12 | — | — | — | -13.1%#9 | — |
| AKBA | $241M#12 | — | 9.7x#9 | 1.0x#2 | 47.5%#4 | 92.4%#2 | 9.9%#1 | -21.2%#3 | — | — | -68.9%#16 | — |
| ALXO | $241M#14 | — | 1.8x#7 | — | — | 24.6%#4 | — | -74.7%#8 | -84.4%#1 | — | 64.6%#3 | — |
| NATR | $232M#15 | 13.2x#1 | 1.7x#6 | 0.5x#1 | 5.7%#8 | 153.7%#1 | 5.2%#2 | 14.3%#1 | — | 9#1 | -20.0%#12 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice